INTENSITY THERAPEUTICS, INC. Other Research and Development Expense
INTENSITY THERAPEUTICS, INC. (INTS) reported Other Research and Development Expense of $1.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherResearchAndDevelopmentExpense · last filed 2026-08-11
- INTENSITY THERAPEUTICS, INC. other research and development expense for the quarter ending 2026-06-30 was $0.00.
- INTENSITY THERAPEUTICS, INC. other research and development expense for the quarter ending 2026-03-31 was $1.20M, a 0.00% change year-over-year.
- INTENSITY THERAPEUTICS, INC. other research and development expense for the quarter ending 2025-12-31 was $0.00.
- INTENSITY THERAPEUTICS, INC. other research and development expense for the quarter ending 2025-09-30 was $0.00.
- INTENSITY THERAPEUTICS, INC. other research and development expense for fiscal 2024 was $1.20M, a 29.41% decline from fiscal 2023.
- INTENSITY THERAPEUTICS, INC. other research and development expense for fiscal 2023 was $1.70M.
| Period end | Other Research and Development Expense 1 month | Other Research and Development Expense 3 month | Other Research and Development Expense 6 month | Other Research and Development Expense 9 month | Other Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.20M 10-Q · filed 2026-08-11 | $1.20M derived: sum of 3 quarters · filed 2026-08-11 | $1.20M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $1.20M 10-Q · filed 2026-05-07 | $1.20M derived: sum of 2 quarters · filed 2026-08-11 | $1.20M derived: sum of 3 quarters · filed 2026-08-11 | $1.20M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-11 | $0.00 derived: sum of 2 quarters · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $1.20M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $1.20M 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.20M 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $1.20M 10-Q · filed 2025-05-13 | ||||
| 2024-12-31 | $1.20M 10-K · filed 2026-03-27 | ||||
| 2023-12-31 | $1.70M 10-Q · filed 2026-08-11 | $1.70M 10-K · filed 2025-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |